Denali Stock Today

DNLI -  USA Stock  

USD 50.48  0.55  1.08%

Denali Therapeutics is trading at 50.48 as of the 2nd of August 2021. This is a -1.08 percent decrease since the beginning of the trading day. The stock's open price was 51.03. Denali Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Denali Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of May 2021 and ending today, the 2nd of August 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Less than 2

Denali Therapeutics Stock Profile

The upcoming quarterly report is expected on the 6th of August 2021. The stock goes through a sell-off trend. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 291 people. more on Denali Therapeutics
Denali Therapeutics generates negative expected return over the last 90 days
Denali Therapeutics has high historical volatility and very poor performance
Denali Therapeutics is unlikely to experience financial distress in the next 2 years
Denali Therapeutics has a strong financial position based on the latest SEC filings
Over 77.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.bioworld.com: Neuro disease stocks fall in July, but Prothena carries the pack for 2021 - BioWorld Online
Denali Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Denali Therapeutics SEC Filings
Denali Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameDenali Therapeutics
CEORyan Watts  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Denali Therapeutics report their recommendations after researching Denali Therapeutics' financial statements, talking to executives and customers, or listening in on Denali Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Denali Therapeutics. The Denali consensus assessment is calculated by taking the average forecast from all of the analysts covering Denali Therapeutics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Denali Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Denali Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 7 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares88.4 M109 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted88.4 M109 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations449 M416.2 M
Significantly Up
Increasing
Slightly volatile
Total Assets1.7 B1.6 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities489.6 M453.7 M
Significantly Up
Increasing
Slightly volatile
Current Assets1.6 B1.5 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities77.4 M71.7 M
Significantly Up
Increasing
Slightly volatile
Total Debt61.6 M62 M
Slightly Down
Decreasing
Slightly volatile
Return on Average Assets0.07660.071
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.290.334
Fairly Down
Increasing
Stable
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Denali Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Denali Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Denali Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Denali Therapeutics' financial leverage. It provides some insight into what part of Denali Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Denali Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Denali Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Denali Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 67.79 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Denali Therapeutics has a current ratio of 25.7, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

449.01 MillionShare
Denali Therapeutics (DNLI) is traded on NASDAQ Exchange in USA. It is located in 161 Oyster Point Boulevard and employs 291 people. Denali Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 6.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Denali Therapeutics's market, we take the total number of its shares issued and multiply it by Denali Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Denali Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 121.18 M outstanding shares of which 6.48 M shares are currently shorted by private and institutional investors with about 13.68 trading days to cover. Denali Therapeutics currently holds about 1.41 B in cash with 420.4 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.69.
Check Denali Therapeutics Probability Of Bankruptcy
Ownership
Denali Therapeutics retains a total of 121.18 Million outstanding shares. The majority of Denali Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Denali Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Denali Therapeutics. Please pay attention to any change in the institutional holdings of Denali Therapeutics as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Denali Ownership Details

Denali Stock Price Odds Analysis

What are Denali Therapeutics' target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Denali Therapeutics jumping above the current price in 90 days from now is under 95%. The Denali Therapeutics probability density function shows the probability of Denali Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Denali Therapeutics has a beta of 0.1612 suggesting as returns on the market go up, Denali Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Denali Therapeutics will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Denali Therapeutics is significantly underperforming DOW.
 Odds Down 50.48HorizonTargetOdds Up 50.48 
5.55%90 days
 50.48 
94.41%
Based on a normal probability distribution, the odds of Denali Therapeutics to move above the current price in 90 days from now is under 95 (This Denali Therapeutics probability density function shows the probability of Denali Stock to fall within a particular range of prices over 90 days) .

Denali Therapeutics Historical Income Statement

Denali Therapeutics Income Statement is one of the three primary financial statements used for reporting Denali's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Denali Therapeutics revenue and expense. Denali Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Denali Therapeutics Net Income is most likely to increase significantly in the upcoming years. The last year's value of Net Income was reported at 71.14 Million. The current Net Income Common Stock is estimated to increase to about 76.8 M, while Operating Expenses is projected to decrease to roughly 228.8 M. View More Fundamentals

Denali Stock Against Markets

Picking the right benchmark for Denali Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Denali Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Denali Therapeutics is critical whether you are bullish or bearish towards Denali Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Denali Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module

Denali Therapeutics Corporate Directors

Denali Therapeutics corporate directors refer to members of a Denali Therapeutics board of directors. The board of directors generally takes responsibility for the Denali Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Denali Therapeutics' board members must vote for the resolution. The Denali Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
David Schenkein - Independent DirectorProfile
Peter Klein - Independent DirectorProfile
Douglas Cole - Independent DirectorProfile
Robert Nelsen - Independent DirectorProfile
Continue to Investing Opportunities. Note that the Denali Therapeutics information on this page should be used as a complementary analysis to other Denali Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Denali Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.